Preparation and Bioavailability Assessment of SMEDDS Containing Valsartan

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2010 Feb 26

PMID 20182825

Citations 31

Authors

Adhvait R Dixit

Sadhana J Rajput

Samir G Patel

Affiliations

Soon will be listed here.

Abstract

A self-microemulsifying drug delivery system (SMEDDS) has been developed to enhance diffusion rate and oral bioavailability of valsartan. The solubility of valsartan was checked in different oils, surfactants, and cosurfactants and ternary phase diagrams were constructed to evaluate the microemulsion domain. The valsartan SMEDDS was prepared using Capmul MCM (oil), Tween 80 (surfactant), and polyethylene glycol 400 (cosurfactant). The particle size distribution, zeta potential, and polydispersity index were determined and were found to be 12.3 nm, -0.746, and 0.138, respectively. Diffusion rate of valsartan was measured by in vitro dialysis bag method using phosphate buffer pH 6.8 as diffusion media. Developed high-performance liquid chromatography method was used to determine drug content in diffusion media. Oral bioavailability of valsartan SMEDDS was checked by using rabbit model. Results of diffusion rate and oral bioavailability of valsartan SMEDDS were compared with those of pure drug solution and of marketed formulation. Diffusion of valsartan SMEDDS showed maximum drug release when compared to pure drug solution and marketed formulation. The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.

Citing Articles

Solid Self-Microemulsifying Drug Delivery System for Improved Oral Bioavailability of Relugolix: Preparation and Evaluation.

Li Z, Deng G, Fang C, Zhao Y, Yuan J, Chen L Int J Nanomedicine. 2025; 20:1065-1082.

PMID: 39886543 PMC: 11780666. DOI: 10.2147/IJN.S497099.

Development and Characterization of Olaparib-Loaded Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Pharmaceutical Applications.

Shin Y, Kim M, Kim C, Jeon H, Koo J, Oh J AAPS PharmSciTech. 2024; 25(7):221.

PMID: 39317842 DOI: 10.1208/s12249-024-02927-2.

Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson's disease.

Bandiwadekar A, Jose J, Gopan G, Augustin V, Ashtekar H, Khot K Drug Deliv Transl Res. 2024; 15(3):1043-1073.

PMID: 38949746 DOI: 10.1007/s13346-024-01656-0.

Lipid Horizons: Recent Advances and Future Prospects in LBDDS for Oral Administration of Antihypertensive Agents.

Preeti , Sambhakar S, Malik R, Bhatia S, Al Harrasi A, Saharan R Int J Hypertens. 2024; 2024:2430147.

PMID: 38410720 PMC: 10896658. DOI: 10.1155/2024/2430147.

Development and Characterization of New Miconazole-Based Microemulsions for Buccal Delivery by Implementing a Full Factorial Design Modeling.

Talianu M, Dinu-Pirvu C, Ghica M, Anuta V, Prisada R, Popa L Pharmaceutics. 2024; 16(2).

PMID: 38399325 PMC: 10893023. DOI: 10.3390/pharmaceutics16020271.

References

Shrivastava A, Ursekar B, Kapadia C . Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv. 2009; 6(1):28-37. DOI: 10.2174/156720109787048258. View

Klauser R, Irschik H, Kletzmayr J, Sturm I, Brunner W, Woloszczuk W . Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: does fat intake still matter?. Transplant Proc. 1997; 29(7):3137-40. DOI: 10.1016/s0041-1345(97)00814-2. View

Constantinides P . Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res. 1995; 12(11):1561-72. DOI: 10.1023/a:1016268311867. View

Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S . Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm. 2007; 57(3):315-32. DOI: 10.2478/v10007-007-0025-5. View

Porter C, Kaukonen A, Boyd B, Edwards G, Charman W . Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004; 21(8):1405-12. DOI: 10.1023/b:pham.0000036914.22132.cc. View

Hauss D, Fogal S, Ficorilli J, Price C, Roy T, Jayaraj A . Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 1998; 87(2):164-9. DOI: 10.1021/js970300n. View

Charman W . Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci. 2000; 89(8):967-78. DOI: 10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r. View

Date A, Nagarsenker M . Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2006; 329(1-2):166-72. DOI: 10.1016/j.ijpharm.2006.08.038. View

Kommuru T, Gurley B, Khan M, Reddy I . Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001; 212(2):233-46. DOI: 10.1016/s0378-5173(00)00614-1. View

10.

Lawrence M, Rees G . Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000; 45(1):89-121. DOI: 10.1016/s0169-409x(00)00103-4. View

11.

Kang B, Lee J, Chon S, Jeong S, Yuk S, Khang G . Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004; 274(1-2):65-73. DOI: 10.1016/j.ijpharm.2003.12.028. View

12.

Gershanik T, Benita S . Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000; 50(1):179-88. DOI: 10.1016/s0939-6411(00)00089-8. View

13.

Lu J, Wang J, Zhao S, Liu X, Zhao H, Zhang X . Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm. 2008; 69(3):899-907. DOI: 10.1016/j.ejpb.2008.02.023. View

14.

Gursoy R, Benita S . Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004; 58(3):173-82. DOI: 10.1016/j.biopha.2004.02.001. View

15.

Macek J, Klima J, Ptacek P . Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 832(1):169-72. DOI: 10.1016/j.jchromb.2005.12.035. View

16.

Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H . Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 2009; 371(1-2):148-55. DOI: 10.1016/j.ijpharm.2008.12.009. View

17.

Wu W, Wang Y, Que L . Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm. 2006; 63(3):288-94. DOI: 10.1016/j.ejpb.2005.12.005. View

18.

Brookman L, Rolan P, Benjamin I, Palmer K, Wyld P, Lloyd P . Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997; 62(3):272-8. DOI: 10.1016/S0009-9236(97)90029-1. View

19.

Zhang P, Liu Y, Feng N, Xu J . Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 2008; 355(1-2):269-76. DOI: 10.1016/j.ijpharm.2007.12.026. View

20.

Patel A, Vavia P . Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J. 2008; 9(3):E344-52. PMC: 2751486. DOI: 10.1208/aapsj0903041. View